We also found significantly decreased LSC populations (0.8428 ± 0.3184% vs 6.38 ± 0.41%; p < 0.0001; Fig. 4L) along with a reduction in CD93+ (positively correlated with leukemia stemness [35]) LSCs (14.1 ± 2.85% vs 27.13 ± 5.06%; p = 0.0007; Supplementary Fig. S3G) in the BM of the 2nd receptor model mice transplanted with AraC- and ADM-treated Psmb10−/− MA9 mouse BM cells, compared to those receiving Psmb10+/+ MA9 cells. This evidence concerns the gene CD93 and leukemia.